Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Highlights

  • Highlights
    Highlights of This Issue
    Mol Cancer Ther May 1 2012 11 (5) 1049-1049;

Reviews

  • Reviews
    Attacking a Nexus of the Oncogenic Circuitry by Reversing Aberrant eIF4F-Mediated Translation
    Peter B. Bitterman and Vitaly A. Polunovsky
    Mol Cancer Ther May 1 2012 11 (5) 1051-1061; DOI:10.1158/1535-7163.MCT-11-0530

  • Reviews
    Immunotherapy of Cancer with 4-1BB
    Dass S. Vinay and Byoung S. Kwon
    Mol Cancer Ther May 1 2012 11 (5) 1062-1070; DOI:10.1158/1535-7163.MCT-11-0677

Therapeutic Discovery

  • Therapeutic Discovery
    Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
    Kian Kani, Vitor M. Faca, Lindsey D. Hughes, Wenxuan Zhang, Qiaojun Fang, Babak Shahbaba, Roland Luethy, Jonathan Erde, Joanna Schmidt, Sharon J. Pitteri, Qing Zhang, Jonathan E. Katz, Mitchell E. Gross, Sylvia K. Plevritis, Martin W. McIntosh, Anjali Jain, Samir Hanash, David B. Agus and Parag Mallick
    Mol Cancer Ther May 1 2012 11 (5) 1071-1081; DOI:10.1158/1535-7163.MCT-11-0852

  • Therapeutic Discovery
    Hyperactivation of 4E-Binding Protein 1 as a Mediator of Biguanide-Induced Cytotoxicity during Glucose Deprivation
    Junichi Matsuo, Yoshinori Tsukumo, Sakae Saito, Satomi Tsukahara, Junko Sakurai, Shigeo Sato, Hiromichi Kondo, Masaru Ushijima, Masaaki Matsuura, Toshiki Watanabe and Akihiro Tomida
    Mol Cancer Ther May 1 2012 11 (5) 1082-1091; DOI:10.1158/1535-7163.MCT-11-0871

  • Therapeutic Discovery
    Off-Target Function of the Sonic Hedgehog Inhibitor Cyclopamine in Mediating Apoptosis via Nitric Oxide–Dependent Neutral Sphingomyelinase 2/Ceramide Induction
    Marisa Meyers-Needham, Jocelyn A. Lewis, Salih Gencer, R. David Sentelle, Sahar A. Saddoughi, Christopher J. Clarke, Yusuf A. Hannun, Haakan Norell, Telma Martins da Palma, Michael Nishimura, Jacqueline M. Kraveka, Zohreh Khavandgar, Monzur Murshed, M. Ozgur Cevik and Besim Ogretmen
    Mol Cancer Ther May 1 2012 11 (5) 1092-1102; DOI:10.1158/1535-7163.MCT-11-0705

  • Therapeutic Discovery
    Evading Pgp Activity in Drug-Resistant Cancer Cells: A Structural and Functional Study of Antitubulin Furan Metotica Compounds
    Tam Luong Nguyen, Maria Rosaria Cera, Andrea Pinto, Leonardo Lo Presti, Ernest Hamel, Paola Conti, Rick Gussio and Peter De Wulf
    Mol Cancer Ther May 1 2012 11 (5) 1103-1111; DOI:10.1158/1535-7163.MCT-11-1018

  • Therapeutic Discovery
    JAK–STAT and JAK–PI3K–mTORC1 Pathways Regulate Telomerase Transcriptionally and Posttranslationally in ATL Cells
    Osamu Yamada, Kohji Ozaki, Masaharu Akiyama and Kiyotaka Kawauchi
    Mol Cancer Ther May 1 2012 11 (5) 1112-1121; DOI:10.1158/1535-7163.MCT-11-0850

Preclinical Development

  • Preclinical Development
    Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo
    Girija Dasmahapatra, Dmitry Lembersky, Minkyeong P. Son, Hiral Patel, Derick Peterson, Elisa Attkisson, Richard I. Fisher, Jonathan W. Friedberg, Paul Dent and Steven Grant
    Mol Cancer Ther May 1 2012 11 (5) 1122-1132; DOI:10.1158/1535-7163.MCT-12-0021

  • Preclinical Development
    The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates
    Hans K. Erickson, Gail D. Lewis Phillips, Douglas D. Leipold, Carmela A. Provenzano, Elaine Mai, Holly A. Johnson, Bert Gunter, Charlene A. Audette, Manish Gupta, Jan Pinkas and Jay Tibbitts
    Mol Cancer Ther May 1 2012 11 (5) 1133-1142; DOI:10.1158/1535-7163.MCT-11-0727

  • Preclinical Development
    ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
    Georgia Hatzivassiliou, Bonnie Liu, Carol O'Brien, Jill M. Spoerke, Klaus P. Hoeflich, Peter M. Haverty, Robert Soriano, William F. Forrest, Sherry Heldens, Huifen Chen, Karen Toy, Connie Ha, Wei Zhou, Kyung Song, Lori S. Friedman, Lukas C. Amler, Garret M. Hampton, John Moffat, Marcia Belvin and Mark R. Lackner
    Mol Cancer Ther May 1 2012 11 (5) 1143-1154; DOI:10.1158/1535-7163.MCT-11-1010

  • Preclinical Development
    Triggering Fbw7-Mediated Proteasomal Degradation of c-Myc by Oridonin Induces Cell Growth Inhibition and Apoptosis
    Hui-Lin Huang, Heng-You Weng, Lu-Qin Wang, Chun-Hong Yu, Qiao-Juan Huang, Pan-Pan Zhao, Jun-Zhi Wen, Hui Zhou and Liang-Hu Qu
    Mol Cancer Ther May 1 2012 11 (5) 1155-1165; DOI:10.1158/1535-7163.MCT-12-0066

  • Preclinical Development
    miRNA-29b Suppresses Prostate Cancer Metastasis by Regulating Epithelial–Mesenchymal Transition Signaling
    Peng Ru, Robert Steele, Philip Newhall, Nancy J. Phillips, Karoly Toth and Ratna B. Ray
    Mol Cancer Ther May 1 2012 11 (5) 1166-1173; DOI:10.1158/1535-7163.MCT-12-0100

  • Preclinical Development | Free Article
    Therapeutic Significance of Estrogen Receptor β Agonists in Gliomas
    Gangadhara R. Sareddy, Binoj C. Nair, Vijay K. Gonugunta, Quan-guang Zhang, Andrew Brenner, Darrell W. Brann, Rajeshwar Rao Tekmal and Ratna K. Vadlamudi
    Mol Cancer Ther May 1 2012 11 (5) 1174-1182; DOI:10.1158/1535-7163.MCT-11-0960

  • Preclinical Development
    Multiple Antigenic Peptides Based on H-2Kb–Restricted CTL Epitopes from Murine Heparanase Induce a Potent Antitumor Immune Response In Vivo
    Xu-Dong Tang, Guo-Zhen Wang, Jun Guo, Mu-Han Lü, Chuan Li, Ning Li, Ya-Ling Chao, Chang-Zhu Li, Yu-Yun Wu, Chang-Jiang Hu, Dian-Chun Fang and Shi-Ming Yang
    Mol Cancer Ther May 1 2012 11 (5) 1183-1192; DOI:10.1158/1535-7163.MCT-11-0607

Molecular Medicine in Practice

  • Molecular Medicine in Practice
    Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
    Terence M. Williams, Athena R. Flecha, Paul Keller, Ashwin Ram, David Karnak, Stefanie Galbán, Craig J. Galbán, Brian D. Ross, Theodore S. Lawrence, Alnawaz Rehemtulla and Judith Sebolt-Leopold
    Mol Cancer Ther May 1 2012 11 (5) 1193-1202; DOI:10.1158/1535-7163.MCT-12-0098

  • Molecular Medicine in Practice
    High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway
    Guénaëlle Levallet, Emmanuel Bergot, Martine Antoine, Christian Creveuil, Adriana O. Santos, Michelle Beau-Faller, Florence de Fraipont, Elisabeth Brambilla, Jérôme Levallet, Franck Morin, Virginie Westeel, Marie Wislez, Elisabeth Quoix, Didier Debieuvre, Fatéméh Dubois, Isabelle Rouquette, Jean-Louis Pujol, Denis Moro-Sibilot, Jacques Camonis and Gérard Zalcman
    Mol Cancer Ther May 1 2012 11 (5) 1203-1213; DOI:10.1158/1535-7163.MCT-11-0899

Retraction

  • Retraction
    Retraction in Part: A Genomic Approach to Identify Molecular Pathways Associated with Chemotherapy Resistance
    Mol Cancer Ther May 1 2012 11 (5) 1214-1215; DOI:10.1158/1535-7163.MCT-12-0210

Correction

  • Correction
    Correction: Narciclasine, a Plant Growth Modulator, Activates Rho and Stress Fibers in Glioblastoma Cells
    Mol Cancer Ther May 1 2012 11 (5) 1216-1217; DOI:10.1158/1535-7163.MCT-12-0327

Back to top
PreviousNext
Molecular Cancer Therapeutics: 11 (5)
May 2012
Volume 11, Issue 5
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Issue Highlights

  • ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
  • Therapeutic Significance of Estrogen Receptor β Agonists in Gliomas
  • Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
  • Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo
  • High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway

Jump to

  • Highlights
  • Reviews
  • Therapeutic Discovery
  • Preclinical Development
  • Molecular Medicine in Practice
  • Retraction
  • Correction
Advertisement
  • Most Cited
  • Most Read
Loading
  • Anti-KIT DNA Aptamer Labeling in GIST
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Tipifarnib as a Precision Therapy for HRAS-Mutant HNSCC
  • Targeted Delivery of MMAE Using Bicycle Molecules
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement